文献速递神经肿瘤

高级别脑膜瘤现代治疗中切除范围与辅助放疗的生存影响

Survival impacts of extent of resection and adjuvant radiotherapy for the modern management of high-grade meningiomas.
PubMed 文献 · J Neurooncol · 2019-09-06

基于SEER数据库2000-2015年530例高级别脑膜瘤(WHO II-III级)的生存分析及92例中山大学肿瘤防治中心队列验证,发现全切除(GTR)与次全切除(STR)的总生存(OS)无显著差异,但GTR与无进展生存(PFS)提高相关;辅助放疗显著改善III级脑膜瘤OS,对II级脑膜瘤的获益不明确。

要点

  • GTR不改善高级别脑膜瘤OS,但可能提高PFS。
  • 辅助放疗可显著改善III级脑膜瘤OS,对II级脑膜瘤效果不确定。
  • 年龄≥65岁、肿瘤直径>6 cm、III级肿瘤与更差OS相关。

核心结论

  • 在现代管理下,GTR不改善高级别脑膜瘤OS,但似乎与PFS增加相关。
  • 放疗作为III级脑膜瘤的补充治疗是合理的,而对II级脑膜瘤的效果仍不确定,需前瞻性研究验证。

研究设计与样本

  • 回顾性队列研究,纳入SEER数据库2000-2015年530例高级别脑膜瘤患者进行生存分析,采用倾向性评分匹配(PSM)减少选择偏倚。
  • 另用中山大学肿瘤防治中心92例患者进行验证。

主要发现

  • SEER队列中,GTR与STR的总生存(OS)无显著差异,即使经过PSM后仍无差异。
  • 多因素分析显示年龄≥65岁(HR 2.22,P < 0.001)、肿瘤直径>6 cm(HR 1.59,P = 0.004)和III级肿瘤(HR 4.31,P < 0.001)与更差OS相关。
  • 分层分析显示辅助放疗显著改善III级脑膜瘤的OS,但对II级脑膜瘤无显著改善,无论切除程度如何。
  • 在SYSUCC队列中,切除程度与OS也无显著关联;但GTR(Simpson I-III级)患者的无进展生存(PFS)显著优于STR(P < 0.001)。
  • 对于GTR后的II级脑膜瘤,放疗未能改善OS和PFS。

临床怎么用

  • 对于高级别脑膜瘤,GTR可能应被视为提高PFS的手段,而非改善OS。
  • III级脑膜瘤患者可考虑辅助放疗以改善OS。
  • II级脑膜瘤的辅助放疗决策需个体化,缺乏明确OS获益证据。

局限性

  • SEER数据库为回顾性数据,可能存在选择偏倚和未测量混杂因素。
  • SYSUCC验证队列样本量较小(92例)。
  • II级脑膜瘤放疗效果需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aim to investigate the impacts of extent of resection and adjuvant radiotherapy on survival of high-grade meningiomas (WHO grade II-III) according to modern diagnosis and management. METHODS: Patients with high-grade meningiomas were identified in the Surveillance Epidemiology and End Results (SEER) database between 2000 and 2015 and used for survival analysis. Propensity score matching (PSM) was conducted to reduce selection bias. Another 92 patients from Sun Yat-sen University Cancer Center (SYSUCC) were used for validation. RESULTS: 530 patients were enrolled from SEER. Patients with gross total resection (GTR) had no significantly different overall survival (OS) compared with those with subtotal resection (STR), even after performing PSM between these two groups. Multivariable analysis found that age ≥ 65 years (HR 2.22, P < 0.001), tumor diameter > 6 cm (HR 1.59, P = 0.004) and grade III tumor (HR 4.31, P < 0.001) were associated with worse OS. Stratification analysis showed that adjuvant radiotherapy conferred significantly improved OS for grade III meningiomas, but not for grade II meningiomas, regardless of resection extent. In SYSUCC cohort, resection extent was also not significantly associated with OS. However, patients with GTR (Simpson grade I-III) had distinctly increased progression-free survival (PFS) than those with STR (P < 0.001). Additionally, for grade II meningiomas after GTR, radiotherapy was unable to improve OS and PFS. CONCLUSION: On modern management of high-grade meningiomas, GTR does not improve OS, but seems to be associated with increased PFS. Radiotherapy is reasonable as a supplement for treating grade III meningiomas, whereas its effect for grade II meningiomas remains uncertain and needs further validation by prospective study.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Li D, Jiang P, Xu S, et al. Survival impacts of extent of resection and adjuvant radiotherapy for the modern management of high-grade meningiomas. J Neurooncol. 2019. PMID: 31493161. doi:10.1007/s11060-019-03278-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。